Alembic Q2 Gets Sartans Shot
Executive Summary
Continuing sartans crisis, new product launches in US help Alembic post strong Q2 performance despite slowdown in other markets.
You may also be interested in...
As US Slows Down, Torrent Aims For Germany, Brazil
A lack of new launches and price erosion caused a sharp dip in Torrent’s Q3 US revenues, but the company plans to ramp up its presence in Brazil and Germany to build momentum. Meanwhile, the field force in India has been downsized with an aim to defocus on older brands.
Jubilant Revenues Flat On LSI Decline
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in the LSI business and FDA action at two manufacturing units.
Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.